Talk:Dementia with Lewy bodies: Difference between revisions

Content deleted Content added

Inline

Latest revision as of 13:46, 6 February 2024

This is the talk page for discussing improvements to the Dementia with Lewy bodies article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Archives: 1, 2, 3, 4: 3 months

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Dementia with Lewy bodies.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Dementia with Lewy bodies is a featured article; it (or a previous version of it) has been identified as one of the best articles produced by the Wikipedia community. Even so, if you can update or improve it, please do so.

This article appeared on Wikipedia's Main Page as Today's featured article on July 21, 2021.

Article milestones
Date	Process	Result
May 31, 2020	Featured article candidate	Promoted

Medicine: Neurology High‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
High	This article has been rated as High-importance on the project's importance scale.
	This article is supported by the Neurology task force.

Neuroscience High‑importance

	This article is within the scope of WikiProject Neuroscience, a collaborative effort to improve the coverage of Neuroscience on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.NeuroscienceWikipedia:WikiProject NeuroscienceTemplate:WikiProject Neuroscienceneuroscience
High	This article has been rated as High-importance on the project's importance scale.

@@ Line 1: / Line 1: @@
 {{talk header}}
 {{Reliable sources for medical articles}}
+{{Article history
-{{ArticleHistory
 |action1 = FAC
 |action1date = 2020-05-31
@@ Line 11: / Line 11: @@
 |maindate= July 21, 2021
 }}
+{{WikiProject banner shell|class=FA|1=
-{{WikiProjectBannerShell|1=
-{{WikiProject Medicine |class=FA|importance=high |neurology=yes}}
+{{WikiProject Medicine |importance=high |neurology=yes}}
-{{WikiProject Neuroscience |class=FA|importance=High}}
+{{WikiProject Neuroscience |importance=High}}
 }}
 {{User:MiszaBot/config
@@ Line 34: / Line 34: @@
 | title       = Dementia with Lewy Bodies: A Review
 | year        = 2019
+| author      = Fymat, Alain L: International Institute of Medicine and Science
-| author      =
-| authorlist  = Fymat, Alain L: International Institute of Medicine and Science
 | url         = https://scientiaricerca.com/srcons/SRCONS-04-00097.php
 | org         =  Scientia Ricerca
@@ Line 42: / Line 41: @@
 | comments    = See [[Talk:Dementia with Lewy bodies/Alain L. Fymat]]
 }}
-== Life expectancy ==
-{{u|Likeanechointheforest}} re [https://en.wikipedia.org/enwiki/w/index.php?title=Dementia_with_Lewy_bodies&diff=1100590527&oldid=1098193463 this edit], please have a look at [[WP:MEDRS]], [[WP:FAOWN]] and [[WP:LEAD]].  Also, take a look at the [[Dementia_with_Lewy_bodies#Prognosis|Prognosis section of the article]], where variability and greater detail is explored.  I removed your edit because it added four citations to the lead, some non-MEDRS, without changing much other than providing a range around which the 2021 review number is based. LEADs are summaries of key points; we can't explore everything about life expectancy in the lead. [[User:SandyGeorgia|'''Sandy'''<span style="color: green;">Georgia</span>]] ([[User talk:SandyGeorgia|Talk]])  18:46, 26 July 2022 (UTC)
-:Armstrong (2021) supports the variability text (already in the infobox and the article body), so I have [https://en.wikipedia.org/enwiki/w/index.php?title=Dementia_with_Lewy_bodies&diff=1100595783&oldid=1100593245 added this text]. [[User:SandyGeorgia|'''Sandy'''<span style="color: green;">Georgia</span>]] ([[User talk:SandyGeorgia|Talk]])  18:52, 26 July 2022 (UTC)
-::Thank you! [[User:Likeanechointheforest|Likeanechointheforest]] ([[User talk:Likeanechointheforest|talk]]) 15:09, 27 July 2022 (UTC)
-:::Likewise! [[User:SandyGeorgia|'''Sandy'''<span style="color: green;">Georgia</span>]] ([[User talk:SandyGeorgia|Talk]])  16:22, 27 July 2022 (UTC)
-== Blood tests ==
-The lead says: "A presumptive diagnosis can be made if several disease features are '''present''', such as symptoms or '''certain results of blood tests''', neuropsychological tests, imaging, and sleep studies."
-But from the text it looks like blood tests are mainly used:
-* To rule out other conditions: "laboratory testing to rule out conditions that may cause symptoms similar to dementia, such as abnormal thyroid function, syphilis, HIV, and vitamin deficiencies."
-* In research: "Other tests to detect alpha-synuclein with blood tests are under study as of 2021."
-Did I miss something? [[User:A455bcd9|A455bcd9]] ([[User talk:A455bcd9|talk]]) 09:30, 12 December 2022 (UTC)
-:I have [https://en.wikipedia.org/enwiki/w/index.php?title=Dementia_with_Lewy_bodies&diff=next&oldid=1126992613 restored older wording], which morphed over time, confusingly as you pointed out!  Thx, {{u|A455bcd9}}. [[User:SandyGeorgia|'''Sandy'''<span style="color: green;">Georgia</span>]] ([[User talk:SandyGeorgia|Talk]])  14:28, 12 December 2022 (UTC)
-::Thanks!
-::I also wonder:
-::# ''"Since 2001, 123iodine-metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy has been used diagnostically in East Asia (principally Japan),[40][135][136] but not in the US."'' => what about the rest of the world? And which countries in East Asia besides Japan? (China? South Korea? Taiwan?)
-::# ''"Commercial skin biopsy tests for DLB are available in the US"'': since when? how much do they cost? I guess these tests were FDA approved, do we know how efficient they are? The following sentence ("the role of these tests in clinical practice has not been established") isn't clear (although the source doesn't say much more unfortunately...)
-::# ''"the FDA has given a 'breakthrough device' authorization for CSF testing"'': when? ([https://www.healio.com/news/neurology/20220125/fda-grants-breakthrough-designation-for-lewy-body-detection-test found this 2022 source] but not RS)
-::[[User:A455bcd9|A455bcd9]] ([[User talk:A455bcd9|talk]]) 14:39, 12 December 2022 (UTC)
-:::Thx, A4; I have an app't this morning, so will respond later today, Bst, [[User:SandyGeorgia|'''Sandy'''<span style="color: green;">Georgia</span>]] ([[User talk:SandyGeorgia|Talk]])  14:54, 12 December 2022 (UTC)
-:::To use: {{cite journal |vauthors=Bousiges O, Blanc F |title=Biomarkers of dementia with Lewy bodies: differential diagnostic with Alzheimer's disease |journal=Int J Mol Sci |volume=23 |issue=12 |date=June 2022 |pmid=35742814 |pmc=9223587 |doi=10.3390/ijms23126371}} [[User:SandyGeorgia|'''Sandy'''<span style="color: green;">Georgia</span>]] ([[User talk:SandyGeorgia|Talk]])  15:22, 12 December 2022 (UTC)
-'''1. Scintigraphy'''
-{{cot|title= From sources}}
-:Tousi (2017): Reduced uptake on metaiodobenzylguanidine myocardial scintigraphy correlates with reduced postganglionic sympathetic cardiac innervation in Lewy body diseases, which can increase specificity for discriminating probable DLB from probable AD in milder cases of dementia. However, the latter is more commonly used in Japan and is not used in the USA. The evidence supporting the benefit of other therapeutic modalities is limited in DLB due to lack of extensive studies.
-:Although there is no direct biomarker of DLB, there are three indicative biomarkers: reduced dopamine transporter uptake in the basal ganglia as demonstrated by SPECT or PET, polysomnographic confirmation of REM sleep without atonia, and low uptake iodine-MIBG myocardial scintigraphy which has gained more recognition in Japan and East Asia [6] but is not used clinically in the USA.
-::6. Manabe Y, Inui Y, Toyama H, Kosaka K. 123I-Metaiodobenzylguanidine myocardial scintigraphy with Curr Treat Options Neurol (2017) 19:42 Page 17 of 19 42 early images alone is useful for the differential diagnosis of dementia with Lewy bodies. Psychiatry Res. 2017;261:75–9. {{PMID|28152401}}
-: Kosaka 2017, Yamada M, Chapter 12, p. 162. Article in a very large book:  sources the 2001, nothing about which countries.
-: Bousiges O, Blanc F (June 2022) MIBG myocardial scintigraphy is an imaging technique for estimating sympathetic nerve damage, which post-mortem studies show as reduced in DLB. These damages are seen in primary heart disease, diabetic neuropathy, and also PD and DLB [42]. For DLB at the stage of dementia, the sensitivity ranges from 68.9% [53] N = 61 DLB (ratio method) to 100% N = 19 DLB (ratio method) [42]. The specificity of MIBG scintigraphy when compared to healthy controls or AD is usually excellent: 87% [53], to 92% [42] N = 19 DLB, ratio method [42,53]. Although MIBG scintigraphy seems to be informative, there is a lack of phase 3 studies to validate this biomarker in its use as a differential diagnostic tool between DLB and AD [54].
-{{cob}}
-The reference to East Asia comes from Tousi (2017), but after scouring new and old sources, I can find no further information specifying which countries.  Bousiges & Blanc explain why it's not used elsewhere, so that might be useful info to include.  Personal opinion:  I suspect it just hasn't taken hold in the rest of the world because it's mostly useful as possible discriminator between DLB and AD (an area still not well defined vis-a-vis biomarkers), and there are other ways of doing that-- that is, a lack of interest or funding in re-inventing the wheel with a new methodology in the Western world.  [[User:SandyGeorgia|'''Sandy'''<span style="color: green;">Georgia</span>]] ([[User talk:SandyGeorgia|Talk]])  18:34, 12 December 2022 (UTC)